NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG). Investor losses must relate to purchases of the Company’s shares between January 12, 2015 and February 27, 2018. This action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased shares of Celgene and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (firstname.lastname@example.org), or visit https://www.ksfcounsel.com/cases/nasdaqgs-celg/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by May 29, 2018.
About the Lawsuit
On February 27, 2018, the Company revealed that the U.S. Food and Drug Administration had issued a refusal-to-file letter rejecting the New Drug Application (“NDA”) for Ozanimod, one of its leading drug candidates, because “the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.” On this news, the price of Celgene’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.